Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Articles|July 16, 2025
Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
The data highlight novel therapies and biomarkers shaping personalized cancer care.
Advertisement
Advertisement
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, showcased significant advances across a range of malignancies, with novel agents, biomarker-driven strategies, and long-term outcomes data offering new insights into cancer treatment with implications for pharmacy practice.
Related to this article
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Advertisement
Advertisement